Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
FDA approves talazoparib plus enzalutamide for a new prostate cancer populationOct 26Regulatory decisionenzalutamidePfizer